Company: PTPI
Filing Date: 2025-02-21
Form Type: 8-K
Source: 0001104659-25-016181
Chunk: 4

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-21
Form: 8-K
Item: Item 9.01
Chunk 4
---
Item 9.01 Financial Statements and Exhibits

(d) Exhibits

  Exhibit      Description                                                                                                                
   Number                                                                                                                                 
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
      4.1      Form of                                                                                                                    
      4.2      Form of                                                                                                                    
      4.3      Form of                                                                                                                    
   10.1 +      Form of Securities                                                                                                         
     99.1      Press                                                                                                                      
      104      Cover Page Interactive                                                                                                     

+Schedules have been omitted from this filing pursuant to Item 601(b)(2) of
Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however,
that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule so furnished. Certain
portions of this exhibit (indicated by “[***]”) have been omitted because they are both (i) not material and (ii) would
be competitively harmful if publicly disclosed.

SIGNATURES

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

                               PETROS PHARMACEUTICALS, INC.                                                     
  Date: February 21, 2025      By:                               /s/ Fady Boctor                                
                                                                 Name: Fady Boctor                              
                                                                 Title: President and Chief Commercial Officer